3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes

Motley Fool2021-06-22

Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（18）

bobbobby
·2021-06-27
wheeee
Reply
Like
Report
HLPA
·2021-06-25
real FOOL talking as always
Reply
2
Report
Wallstrtbets
·2021-06-23
Tesla?
Reply
2
Report
CookInSuit
·2021-06-23
Tesla has the halo effect. Wonder when Elon will wear out his halo..
Reply
Like
Report
Eded
·2021-06-23
Other stocks like Shopify and meli also overpriced …
Reply
Like
Report
Popcornn
·2021-06-23
Wow
Reply
Like
Report
iSaac
·2021-06-23
Hello
Reply
Like
Report
azizizizi
·2021-06-23
tesla tho
Reply
Like
Report
Kaesonlim
·2021-06-23
Wow
Reply
Like
Report
Gettingthere
·2021-06-23
Snowflake, in my watchlist
Reply
2
Report
Windfall10
·2021-06-23
Post
Reply
2
Report
Fold Replies
- Windfall10:
  post
  2021-06-23
  Reply
  Report
flydiamond
·2021-06-23
Oo
Reply
2
Report
Fold Replies
- Windfall10:
  comments
  2021-06-23
  Reply
  Report
jiayanliaw
·2021-06-23
?
Reply
1
Report
雨天不撑伞
·2021-06-23
[Observation]
Reply
1
Report
1000010101O
·2021-06-23
??
Reply
1
Report
Ronn
·2021-06-22
Completely agree with this
Reply
1
Report
dpyc
·2021-06-22
Pl like n comment
Reply
1
Report
Fold Replies
- 雨天不撑伞:
  Done
  2021-06-23
  Reply
  Report
- Anneater:
  K
  2021-06-22
  Reply
  Report
S土豪熊貓G
·2021-06-22
Foolishness to listen Fool. They are waiting for the dip to buy in. Know them too well.
Reply
6
Report
Fold Replies
- dpyc:
  Yes
  2021-06-22
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2145599620?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-06-22 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2145599620","market":"us","top_or_hot":-1,"title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","media":"Motley Fool","content":"<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","article_id":"2145599620","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","pubTimestamp":1624371180,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"A lower price won't address these other risks.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"translate_title":"即使市场崩溃我也不会买的三只价格过高的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9,"SNOW":0.9,"TSLA":0.9},"content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","kind":null,"is_publish_news":false,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":124735058,"gmtCreate":1624790548774,"gmtModify":1703845190924,"author":{"id":"3562274010627887","authorId":"3562274010627887","name":"bobbobby","avatar":"https://static.tigerbbs.com/83be380ba55b7bc5658f5f9b34bbb66c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3562274010627887","authorIdStr":"3562274010627887"},"htmlText":"wheeee","listText":"wheeee","text":"wheeee","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/124735058","repostId":2145599620,"repostType":2,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":122882999,"gmtCreate":1624610776111,"gmtModify":1703841670907,"author":{"id":"3569274903458035","authorId":"3569274903458035","name":"HLPA","avatar":"https://static.tigerbbs.com/07e7b987a9127c5a47dbc3ae02db548b","vip":1,"hat":"https://static.tigerbbs.com/646756f1284a5a6480ed02cc4fa7d1d2","crmLevel":8,"crmLevelSwitch":1,"idStr":"3569274903458035","authorIdStr":"3569274903458035"},"htmlText":"real FOOL talking as always","listText":"real FOOL talking as always","text":"real FOOL talking as always","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/122882999","repostId":2145599620,"repostType":2,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":123229703,"gmtCreate":1624425668902,"gmtModify":1703836314012,"author":{"id":"3566244878628904","authorId":"3566244878628904","name":"Wallstrtbets","avatar":"https://static.tigerbbs.com/6c38bbee1121ea92508ad9508fa15c5e","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3566244878628904","authorIdStr":"3566244878628904"},"htmlText":"Tesla?","listText":"Tesla?","text":"Tesla?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123229703","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":123122244,"gmtCreate":1624412935588,"gmtModify":1703835894164,"author":{"id":"3582529687850113","authorId":"3582529687850113","name":"CookInSuit","avatar":"https://static.tigerbbs.com/1a79bf61194a552988070fe312f320ed","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3582529687850113","authorIdStr":"3582529687850113"},"htmlText":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","listText":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","text":"Tesla has the halo effect. Wonder when Elon will wear out his halo..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123122244","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":123946481,"gmtCreate":1624407514443,"gmtModify":1703835638656,"author":{"id":"3581980965309451","authorId":"3581980965309451","name":"Eded","avatar":"https://static.tigerbbs.com/41a629a3014601072ee8dc2d151d1796","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581980965309451","authorIdStr":"3581980965309451"},"htmlText":"Other stocks like Shopify and meli also overpriced …","listText":"Other stocks like Shopify and meli also overpriced …","text":"Other stocks like Shopify and meli also overpriced …","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123946481","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":123051889,"gmtCreate":1624404498041,"gmtModify":1703835477628,"author":{"id":"3574394359789498","authorId":"3574394359789498","name":"Popcornn","avatar":"https://static.tigerbbs.com/a9963e628c84bc7aa6308556a38d7360","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574394359789498","authorIdStr":"3574394359789498"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123051889","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":123025039,"gmtCreate":1624404318821,"gmtModify":1703835467240,"author":{"id":"3559556262240609","authorId":"3559556262240609","name":"iSaac","avatar":"https://static.tigerbbs.com/dda49cbd870fdcc56a2dace4614d8ede","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3559556262240609","authorIdStr":"3559556262240609"},"htmlText":"Hello&nbsp;","listText":"Hello&nbsp;","text":"Hello","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123025039","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":123018780,"gmtCreate":1624403364840,"gmtModify":1703835422851,"author":{"id":"3574244668143937","authorId":"3574244668143937","name":"azizizizi","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574244668143937","authorIdStr":"3574244668143937"},"htmlText":"tesla tho","listText":"tesla tho","text":"tesla tho","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123018780","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":123005951,"gmtCreate":1624402125173,"gmtModify":1703835385947,"author":{"id":"3576132871598457","authorId":"3576132871598457","name":"Kaesonlim","avatar":"https://static.tigerbbs.com/bbfbb39017d97aaac2eaa2f63304059a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576132871598457","authorIdStr":"3576132871598457"},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/123005951","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":129720185,"gmtCreate":1624398569347,"gmtModify":1703835320887,"author":{"id":"3561969095601341","authorId":"3561969095601341","name":"Gettingthere","avatar":"https://static.tigerbbs.com/ea6e10c8465d768ba9679f3f87f9baea","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3561969095601341","authorIdStr":"3561969095601341"},"htmlText":"Snowflake, in my watchlist&nbsp;","listText":"Snowflake, in my watchlist&nbsp;","text":"Snowflake, in my watchlist","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129720185","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":129760985,"gmtCreate":1624397348547,"gmtModify":1703835306297,"author":{"id":"3581834933175279","authorId":"3581834933175279","name":"Windfall10","avatar":"https://static.tigerbbs.com/ff7812fc4f6d030648888d978fc206d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581834933175279","authorIdStr":"3581834933175279"},"htmlText":"Post","listText":"Post","text":"Post","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129760985","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4961750,"gmtCreate":1624397362861,"gmtModify":1635251383593,"authorId":3581834933175279,"author":{"id":3581834933175279,"idStr":"3581834933175279","authorId":3581834933175279,"name":"Windfall10","avatar":"https://static.tigerbbs.com/ff7812fc4f6d030648888d978fc206d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":129760985,"type":1,"supId":0,"prevId":0,"content":"<u>post</u>","text":"<u>post</u>","html":"<u>post</u>"}],"langContent":"EN"},{"id":129704427,"gmtCreate":1624387474369,"gmtModify":1703835250206,"author":{"id":"3581657181534246","authorId":"3581657181534246","name":"flydiamond","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581657181534246","authorIdStr":"3581657181534246"},"htmlText":"Oo","listText":"Oo","text":"Oo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129704427","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4961753,"gmtCreate":1624397380034,"gmtModify":1663229746757,"authorId":3581834933175279,"author":{"id":3581834933175279,"idStr":"3581834933175279","authorId":3581834933175279,"name":"Windfall10","avatar":"https://static.tigerbbs.com/ff7812fc4f6d030648888d978fc206d1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":129704427,"type":1,"supId":0,"prevId":0,"content":"<u>comments</u>","text":"<u>comments</u>","html":"<u>comments</u>"}],"langContent":"EN"},{"id":129444632,"gmtCreate":1624384295526,"gmtModify":1703835221493,"author":{"id":"3582851715516809","authorId":"3582851715516809","name":"jiayanliaw","avatar":"https://static.tigerbbs.com/945cd27367cdafc7a9be69d0e4ceb2e9","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582851715516809","authorIdStr":"3582851715516809"},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129444632","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":129452798,"gmtCreate":1624383197214,"gmtModify":1703835205088,"author":{"id":"3581720011615234","authorId":"3581720011615234","name":"雨天不撑伞","avatar":"https://static.tigerbbs.com/8722060ea3af0a91b655bd116ce76ae5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581720011615234","authorIdStr":"3581720011615234"},"htmlText":"[Observation]&nbsp;","listText":"[Observation]&nbsp;","text":"[Observation]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129452798","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":129545746,"gmtCreate":1624378918385,"gmtModify":1703835081476,"author":{"id":"3581326346667529","authorId":"3581326346667529","name":"1000010101O","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581326346667529","authorIdStr":"3581326346667529"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129545746","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":129291471,"gmtCreate":1624372998693,"gmtModify":1703834832884,"author":{"id":"3577490655979562","authorId":"3577490655979562","name":"Ronn","avatar":"https://static.tigerbbs.com/01315438398478d6a6ee536786f189dd","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577490655979562","authorIdStr":"3577490655979562"},"htmlText":"Completely agree with this&nbsp;","listText":"Completely agree with this&nbsp;","text":"Completely agree with this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/129291471","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":129299867,"gmtCreate":1624372918759,"gmtModify":1703834829414,"author":{"id":"3582979456757749","authorId":"3582979456757749","name":"dpyc","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3582979456757749","authorIdStr":"3582979456757749"},"htmlText":"Pl like n comment","listText":"Pl like n comment","text":"Pl like n comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/129299867","repostId":2145599620,"repostType":4,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4960835,"gmtCreate":1624383214120,"gmtModify":1663229743958,"authorId":3581720011615234,"author":{"id":3581720011615234,"idStr":"3581720011615234","authorId":3581720011615234,"name":"雨天不撑伞","avatar":"https://static.tigerbbs.com/8722060ea3af0a91b655bd116ce76ae5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":129299867,"type":1,"supId":4958418,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":4958418,"gmtCreate":1624375128137,"gmtModify":1663229731840,"authorId":3581571807225162,"author":{"id":3581571807225162,"idStr":"3581571807225162","authorId":3581571807225162,"name":"Anneater","avatar":"https://static.tigerbbs.com/dd99ef969b35027be1194d21c5482e54","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":129299867,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"EN"},{"id":129203338,"gmtCreate":1624372601224,"gmtModify":1703834816089,"author":{"id":"3578811676095048","authorId":"3578811676095048","name":"S土豪熊貓G","avatar":"https://static.tigerbbs.com/2bf36dcb8e5b590c1e5f4df466413275","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3578811676095048","authorIdStr":"3578811676095048"},"htmlText":"Foolishness to listen Fool. They are waiting for the dip to buy in. Know them too well.&nbsp;","listText":"Foolishness to listen Fool. They are waiting for the dip to buy in. Know them too well.&nbsp;","text":"Foolishness to listen Fool. They are waiting for the dip to buy in. Know them too well.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/129203338","repostId":2145599620,"repostType":2,"repost":{"id":"2145599620","pubTimestamp":1624371180,"share":"https://ttm.financial/m/news/2145599620?lang=&edition=fundamental","pubTime":"2021-06-22 22:13","market":"us","language":"en","title":"3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes","url":"https://stock-news.laohu8.com/highlight/detail?id=2145599620","media":"Motley Fool","summary":"A lower price won't address these other risks.","content":"<p>Last week was a rough <a href=\"https://laohu8.com/S/AONE\">one</a> for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.</p>\n<p>Three stocks that I probably wouldn't buy even if the markets were to crash are&nbsp;<b>Ocugen&nbsp;</b>(NASDAQ:OCGN),&nbsp;<b>Tesla&nbsp;</b>(NASDAQ:TSLA), and&nbsp;<b><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>&nbsp;</b>(NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.</p>\n<p><img src=\"https://static.tigerbbs.com/a1531106e22f32af06a047425395b675\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>1. Ocugen</h3>\n<p>Retail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.</p>\n<p>With nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated <i>no revenue</i> in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.</p>\n<p>A market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not <a href=\"https://laohu8.com/S/AONE.U\">one</a> I'd be willing to take a chance on.</p>\n<h3>2. Tesla</h3>\n<p>Tesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the <b>S&amp;P 500</b>.The company has turned itself into a much more formidable investment.</p>\n<p>However, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the&nbsp;<b>SPDR S&amp;P 500 ETF Trust</b> trades at multiples of just 2.9 times sales and 26 times earnings.&nbsp; As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.</p>\n<p>The other problem I have with Tesla is its potential exposure to <b>Bitcoin</b> (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.</p>\n<p>Musk has an impressive following,&nbsp;but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.</p>\n<h3>3. Snowflake</h3>\n<p>Of the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.</p>\n<p>And competition for cloud-based data and analytics can be fierce. Companies such as <b>Amazon.com</b>, <b>Microsoft</b>, and <b>Alphabet&nbsp;</b>are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services.&nbsp;For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.</p>\n<p>Those risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Obscenely Overpriced Stocks I Wouldn't Buy Even if the Market Crashes\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","TSLA":"特斯拉","SNOW":"Snowflake"},"source_url":"https://www.fool.com/investing/2021/06/22/3-obscenely-overpriced-stocks-i-wouldnt-buy-even-i/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145599620","content_text":"Last week was a rough one for the markets -- their worst since October. And with talk of interest rate increases coming sooner than expected, investors are on edge with concerns about a possible stock-market crash. Of course, if a crash does happen, it could create opportunities to pick up solid stocks at reduced prices. But there are other stocks I'm not so sure about.\nThree stocks that I probably wouldn't buy even if the markets were to crash are Ocugen (NASDAQ:OCGN), Tesla (NASDAQ:TSLA), and Snowflake (NYSE:SNOW). Although a lower price might make them more tenable investments, there's still sufficient risk in these stocks for me to pass on them.\n\nImage source: Getty Images.\n1. Ocugen\nRetail investors have been excited about Ocugen's stock this year, but I don't share that enthusiasm. The business's hopes rest on Covaxin, a coronavirus vaccine candidate it is co-developing with India's Bharat Biotech. The companies' agreement stipulates that Ocugen will only share in the profits from sales in Canada and the U.S. -- and prospects for the latter market took a hit this month, when the company said it would no longer seek an emergency use approval for Covaxin from the U.S. Food and Drug Administration (FDA). Instead, on the FDA's recommendation, it will seek a biologics license application that will take longer to obtain, possibly up to 10 months. Even if Covaxin wins approval, the vaccine may no longer be needed by then, with vaccination rates continuing to climb.\nWith nothing else in its pipeline that has even made it to phase 2, Ocugen without Covaxin is back to being a high-risk biotech stock that may or may not someday have a product available to sell. And that brings tons of risk for investors. The company generated no revenue in the first three months of 2021, and that alone is a big enough reason to stay away from this healthcare stock. When you take away the meme hype, there isn't much reason or substance behind an investment in Ocugen.\nA market crash may bring down its price, but even if it were to fall to less than $1, Ocugen would still be a risky buy and not one I'd be willing to take a chance on.\n2. Tesla\nTesla isn't a bad business, and I get why people are fans of it. The electric-vehicle maker has significant potential as the demand rises for more environmentally friendly cars. And Tesla has come a long way in strengthening its financials. Once consistently in the red, it was profitable over the past 12 months -- and has even been included in the S&P 500.The company has turned itself into a much more formidable investment.\nHowever, at 3%, its net margins are still razor-thin. The stock trades at more than 19 times revenue and a staggering 620 times its profits. The average holding in the SPDR S&P 500 ETF Trust trades at multiples of just 2.9 times sales and 26 times earnings.  As with Ocugen, retail investors have driven up the price of Tesla's stock to obscene levels, making it hard to buy shares of what otherwise could be a solid long-term investment.\nThe other problem I have with Tesla is its potential exposure to Bitcoin (CRYPTO: BTC). CEO Elon Musk has been flip-flopping on whether his company will accept the cryptocurrency for payments on vehicles. If Musk decides that Tesla should do so, that exposes the company to a lot of risk. All currencies normally fluctuate somewhat, but Bitcoin's volatility could send a company's financials on a wild roller coaster ride.\nMusk has an impressive following, but his leadership style adds an element of risk to an already expensive and vulnerable stock. A crash in the markets would probably make Tesla's stock cheaper, but for me, it wouldn't be enough to offset the level of risk involved.\n3. Snowflake\nOf the three stocks on this list, Snowflake is the one I'd be most likely to buy. My biggest concerns with this business relate to its competitiveness and ability to turn a profit. Although sales have been increasing -- for the three months ending April 30, they more than doubled to $229 million from the prior-year period -- the company's losses have also doubled during that time.\nAnd competition for cloud-based data and analytics can be fierce. Companies such as Amazon.com, Microsoft, and Alphabet are some of the bigger names in the space -- and to complicate things, Snowflake also uses their services. For now, there appears to be enough room for all these major players to co-exist, but that still poses a risk to Snowflake's business. The lack of a sustainable competitive advantage, or moat, makes the stock particularly vulnerable should one of these larger companies try to expand and fight for more market share.\nThose risks make it hard to stomach the stock's whopping price-to-sales multiple, which sits at 90. Even with a significant correction in price, the lack of profitability and dependence on companies that could pose threats to Snowflake's long-term business would be enough of a reason for me to pass on the company and opt for more attractive growth opportunities instead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4957750,"gmtCreate":1624372936154,"gmtModify":1663229730743,"authorId":3582979456757749,"author":{"id":3582979456757749,"idStr":"3582979456757749","authorId":3582979456757749,"name":"dpyc","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":129203338,"type":1,"supId":0,"prevId":0,"content":"Yes","text":"Yes","html":"Yes"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":66,"commentSize":18,"repostSize":0,"favoriteSize":1,"likeStatus":false,"favoriteStatus":false}}